Finding your way with GIST?
A clinical trial of avapritinib for people with advanced GIST
NAVIGATOR is a phase 1 clinical trial that is designed to test the safety and clinical activity of an investigational drug called avapritinib in people with advanced gastrointestinal tumors (GIST).
Avapritinib selectively targets two kinase proteins called KIT and PDGFRα. Certain mutations (genetic alterations) in these proteins are known to be involved in the development of GIST. In fact, 80% of people with GIST have one or more KIT mutations, and around 5-6% have a specific mutation in PDGFRα called D842V. Avapritinib was developed to selectively target these mutated proteins, and inhibit (block) their activity. Avapritinib is an investigational drug currently being evaluated in clinical trials. It is an oral drug that is taken by mouth once a day.
Trial phase: Phase 1
Trial status: Active and recruiting participants
Enrollment goal: 250 people
100% Chance of receiving active treatment
Tumor imaging by computerized tomography (CT) and/or magnetic resonance imagine (MRI)
Heart monitoring (ECG)
Additional assessments may be required and will be explained to you by the trial doctor.
A travel support program is available for participants and caregivers to reduce out-of-pocket expenses and ensure travel to the trial site is simple and comfortable.
More information about this clinical trial, including participating trial sites, is available on ClinicalTrials.gov
If you think you meet the criteria specified above and are interested in taking part in the NAVIGATOR clinical trial, or you would simply like more information, please call: 617-714-6707 or email email@example.com A member of our team will talk you through the next steps, and will connect you to a suitable trial doctor.